Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832
2025 · 4th Quarter (Oct 1 - Dec 31)
VERTEX PHARMACEUTICALS INCORPORATED
Filed by STANTON PARK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- STANTON PARK GROUP
- Filing UUID
- 4c9f1f1d-be12-4432-9697-38e2b2e7db2f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.